History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
No history of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components;
No history of severe hypersensitivity to a monoclonal antibody
History of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibody.
Grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy
History of allergy to study drug components or history of severe hypersensitivity reaction of any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)
Has had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
Has had a severe hypersensitivity reaction to treatment with another mAb
Previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
Previous severe hypersensitivity reaction to treatment with another monoclonal antibody.
Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody/components of the study treatment(s).
Any history of a severe hypersensitivity reaction to any monoclonal antibody
Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody (mAb).
History of severe hypersensitivity reaction to any monoclonal antibody
Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
Patients with a history of allergy to study drug components or history of a severe hypersensitivity reaction to any monoclonal antibody
Previous severe hypersensitivity reaction to another monoclonal antibody, such as colitis or pneumonitis requiring treatment with steroids, or has a history of interstitial lung disease.
Patients with a history severe (>= grade 3) hypersensitivity reaction to a monoclonal antibody are ineligible
EXCLUSION CRITERIA FOR STRATUM C: Patients with a history severe (>= grade 3) hypersensitivity reaction to a monoclonal antibody are ineligible
History of hypersensitivity reaction to human or mouse antibody products
No prior severe infusion reaction to a monoclonal antibody
History of severe hypersensitivity reaction to treatment with another monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody.
No prior severe infusion reaction to cetuximab or a monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody.
History of severe hypersensitivity reaction to another monoclonal antibody
Any history of a sever hypersensitivity reaction to any monoclonal antibody
Any history of a sever hypersensitivity reaction to any monoclonal antibody
Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody (mAb) therapy
History of severe hypersensitivity reaction to any monoclonal antibody.
History of severe hypersensitivity reaction to any monoclonal antibody including pembrolizumab
Severe hypersensitivity reaction to treatment during prior administration of a monoclonal antibody (mAb) or history of allergy to any study drug component
History of hypersensitivity reaction to human or mouse antibody products
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to Cremaphor EL
History of severe hypersensitivity reaction to any monoclonal antibody and/or to study drug components
History of severe hypersensitivity reaction to any monoclonal antibody
History of hypersensitivity reaction to human or mouse antibody products
Patients with allergies or adverse drug reactions to the following are not eligible:\r\n* History of allergy to study drug components;\r\n* History of severe hypersensitivity reaction to any monoclonal antibody
Allergies and adverse drug reaction; a) history of allergy to study drug components; b) history of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody or study drug components
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Previous severe hypersensitivity reaction to another monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of allergy or adverse drug reaction to the study drug components (nivolumab, dabrafenib, or trametinib) or drugs of similar chemical or biologic composition; patients with a history of severe hypersensitivity reaction to any monoclonal antibody should also be excluded
History of hypersensitivity reaction to human or mouse antibody products
Allergies and adverse drug reaction to the following: history of allergy to study drug components; history of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Prior severe infusion reaction to a monoclonal antibody
Known severe (grade 3 or 4) infusion-related allergy or hypersensitivity to any monoclonal antibody
Allergies and adverse drug reaction\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: History of severe hypersensitivity reaction to any monoclonal antibody
History of allergy to study drug components or history of severe hypersensitivity reaction of any monoclonal antibody
Severe hypersensitivity reaction to treatment with another monoclonal antibody
Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) or interferon-alpha2b (IFN-a2b)
Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody therapy
History of severe hypersensitivity reaction to any monoclonal antibody
Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
Patients with a history of severe (grade >= 3) hypersensitivity reaction to a monoclonal antibody are ineligible
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components or nivolumab, or history of severe hypersensitivity reaction to any monoclonal antibody
Patients who have had a prior severe infusion reaction to a monoclonal antibody are not eligible
Any history of a severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
No prior severe infusion reaction to a monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Prior severe infusion reaction to a monoclonal antibody
Allergies and Adverse Drug Reaction a) History of allergy to study drug components b) History of severe hypersensitivity reaction to any monoclonal antibody
Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb).
History of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components
Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
Allergies and adverse drug reaction\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibody
Current or past history of severe hypersensitivity to any other antibody products
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to taxanes
History of severe hypersensitivity reaction to any monoclonal antibody
Prior severe infusion reaction to a monoclonal antibody
Severe hypersensitivity reaction to treatment with another monoclonal antibody
Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)
Patients who previously had a severe reaction to treatment with a human antibody.
History of hypersensitivity reaction to human or mouse antibody products
Participant has previous severe hypersensitivity reaction to another monoclonal antibody (mAb).
History of severe hypersensitivity reaction to any monoclonal antibody
Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
No prior severe infusion reaction to cetuximab or a monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction (>= grade 3) to docetaxel
Previous serious hypersensitivity reaction to monoclonal antibodies. (Determination of \serious\ hypersensitivity reaction is at the investigator's discretion.)
History of hypersensitivity reaction to human or mouse antibody products
History of severe hypersensitivity reaction to any monoclonal antibody
Has a history of a severe hypersensitivity reaction to treatment with another monoclonal antibody
Severe hypersensitivity reaction to treatment with another monoclonal antibody, known or suspected hypersensitivity to study drugs or any component of their formulation.
Has had a severe hypersensitivity reaction to treatment with another monoclonal antibody
History of allergy to study drug components or of severe hypersensitivity reaction to any monoclonal antibody
History of severe reaction to prior monoclonal antibody therapy (defined as a Grade 4 event and/or requiring permanent discontinuation)
A history of a severe hypersensitivity reaction to ipilimumab or dabrafenib
History of severe infusion reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of hypersensitivity reaction to human or mouse antibody products
Prior severe infusion-related reaction to a monoclonal antibody
Prior severe infusion reaction to a monoclonal antibody
History of hypersensitivity reaction to human or mouse antibody products
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
No intervening anti-cancer therapy between the last course of nivolumab or pembrolizumab and the first dose of study treatment is allowed except for local measures (e.g., surgical excision or biopsy, focal radiation therapy).
The interval between last nivolumab or pembrolizumab and start of study treatment should be at least 21 days with no residual anti-PD-1-related immune toxicities in excess of Grade 1 severity.
Ongoing or recent use of a checkpoint inhibitor agent (eg ipilimumab, pembrolizumab, nivolumab) within three drug half-lives from the most recent dose to Cycle 1 Day 1
Has participated in Merck MK-3475 (pembrolizumab) clinical trials
Any investigational agents, anti-cancer monoclonal antibody, anti-cancer therapeutic vaccine, immunostimulant (e.g. IL-2) or study drugs from a previous clinical study within 4 weeks of the first dose of mRNA-4157 or pembrolizumab (note only a 2 week wash out is required from prior pembrolizumab treatment)
Hypersensitivity to pembrolizumab or any of its recipients
Has participated in any other pembrolizumab trial and has been treated with pembrolizumab.
Patients currently on Pembrolizumab and achieve a less than complete response
Has received prior sunitinib or pembrolizumab therapy for the treatment of malignancy
Prior treatment with immunotherapy (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab) within 6 months of cycle 1 day 1
Patient must currently be receiving systemic PD-1 immunotherapy with pembrolizumab or nivolumab to be eligible; patients who are receiving combination ipilimumab with pembrolizumab or nivolumab are not eligible
Must have been off immunosuppressive therapy for >= 7 days before receiving first dose of pembrolizumab
Has been on immunosuppressant therapy within 7 days prior to the first dose of pembrolizumab
Hypersensitivity to pembrolizumab or any of its recipients
Patients who have received any checkpoint inhibitor, including ipilimumab, nivolumab, pembrolizumab or others.
Investigator determined assessment of disease progression after treatment with pembrolizumab monotherapy, OR
Most recent prior regimen was a PD-1 inhibitor (nivolumab or pembrolizumab) with progression; last dose must have been delivered within 90 days of enrollment
Has had prior treatment with pembrolizumab
Patients who have participated in pembrolizumab (MK-3475) Merck studies
Allergy to pembrolizumab or related compounds
Has received prior therapy with pembrolizumab
Patients with Stage IIIB/IV squamous or non-squamous NSCLC (American Joint Committee on Cancer 7th Edition Staging) who have had prior treatment with nivolumab or pembrolizumab will be enrolled in one of 3 parallel cohorts based on the following:\r\n* Cohort 1: patient with progressive disease on nivolumab or pembrolizumab as the BOR; progressive disease must be confirmed with a confirmatory scan ? 4 weeks after the 1st documented date of progression\r\n* Cohort 2: patients with stable disease as the BOR on a minimum of 12 weeks of therapy with nivolumab or pembrolizumab\r\n* Cohort 3: patients with partial or complete response as the BOR, followed by progressive disease, on nivolumab or pembrolizumab; a confirmatory scan at the time of disease progression must be performed ? 4 weeks after the 1st documented date of progression
Any prior severe adverse event attributed to prior anti-PD1 therapy that, in the Principal investigator's opinion, would contraindicate pembrolizumab administration such as:
Has a diagnosis of immunodeficiency; note that patients should not receive steroids during pembrolizumab administration
Prior pancreatitis that was symptomatic or required medical intervention =< 6 months prior to registration (known toxicity of pembrolizumab)
Prior enteritis that was symptomatic or required medical intervention =< 6 months prior to registration (known toxicity of pembrolizumab)
Uncontrolled hyper/hypothyroidism or hyper/hypocorticism =< 6 months prior to registration (known toxicity of pembrolizumab)
Has received systemic therapy within 4 weeks of the first dose of pembrolizumab
Patients who have received thoracic radiation > 30 gray (Gy) within six months of the first dose of pembrolizumab
Stage III or stage IV metastatic melanoma as defined on imaging studies performed within 28 days of first dose of pembrolizumab and clinical exam performed within 14 days of first dose of pembrolizumab
Has known hypersensitivity to MK-3475 (pembrolizumab) or any of its incipients
Subject has a known hypersensitivity to pembrolizumab or any of its ingredients
Has known hypersensitivity to pembrolizumab (MK-3475) or its formulation
Current treatment of at least 3 months with pembrolizumab or nivolumab (no more than 1 cycle / 6 weeks of treatment interruption immediately prior to study enrollment)
Experienced a previous response to pembrolizumab or nivolumab
Patients in which treatment with pembrolizumab and nivolumab is contraindicated
Required screening laboratory data (within 28 days prior to administration of pembrolizumab)
For male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugs
Dose escalation cohort: histologically or cytologically confirmed diagnosis of a solid tumor that can be treated with either pembrolizumab or nivolumab as part of standard of care or whom no standard of therapy exists except pembrolizumab or nivolumab
Requires or may require treatment with high-dose systemic corticosteroids within 2 weeks of the start of intravenous pembrolizumab infusions and within 2 weeks following the first infusion of pembrolizumab
Planned standard treatment with pembrolizumab
Known hypersensitivity to pembrolizumab or any of its insipients
Has participated in a previous trial and received pembrolizumab therapy
Known hypersensitivity to pembrolizumab or another mAb.
Prior pembrolizumab
A patient must have previously received anti-PD1 immunotherapy (nivolumab or pembrolizumab) and later experienced disease progression, within 3 months of registration on this study
Ongoing or recent use of a checkpoint inhibitor (eg, nivolumab, pembrolizumab, ipilimumab) within three drug half-lives from the most recent dose to Cycle 1 Day 1
Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogs
Patients must have histologically or cytologically confirmed malignant neoplasms (not including hematological malignancies and brain tumors) untreated or previously treated requiring further treatment; patients must be refractory to, and intolerant of, established therapy known to provide clinical benefit for their condition; patients in Arm L (pembrolizumab) and Arm M (nivolumab) can be treatment naïve and do not have to fail first line nivolumab or pembrolizumab if they have disease where pembrolizumab or nivolumab are Food and Drug Administration (FDA) approved for the first-line setting
Patient has hypersensitivity to boron, mannitol sucrose, histidine (as base and hydrochloride salt) and polysorbate 80 or any of the components of study therapy including required prophylactic medications
Patients with hypersensitivity to bortezomib, boron or mannitol.
Known hypersensitivity to Velcade, boron, or mannitol
Known or suspected hypersensitivity to 5-azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Known hypersensitivity to azacitidine or mannitol
Have a history of allergic (anaphylactic) sensitivity to bortezomib, boron or mannitol
History of allergy to mannitol
History of hypersensitivity to mannitol
Subjects must not have a known history of hypersensitivity to mannitol
Must not have a known or suspected hypersensitivity to azacitidine, mannitol, or compounds of similar composition to azacitidine
Patient with hypersensitivity to bortezomib, boron or dexamethasone
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to any of the following: bortezomib, boron, mannitol
Known allergy or hypersensitivity to azacitidine, mannitol, or midostaurin
Previous history of hypersensitivity to bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
Participant who has hypersensitivity to bortezomib, boron, or mannitol
Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate 80.
Known or suspected hypersensitivity to azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine, mannitol, or durvalumab, its constituents, or to any other humanized monoclonal antibody.
Patient has hypersensitivity to bortezomib, boron or mannitol
Known hypersensitivity to mannitol.
Has a known hypersensitivity to azacitidine or mannitol
Patients with known allergy to sorafenib or azacitidine, mannitol or any of their components
Patients must not have a known allergy to mannitol
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
Patients must not have hypersensitivity to bortezomib, boron or mannitol
Participant has a known or suspected hypersensitivity to azacitidine, mannitol, or any other ingredient used in the manufacture of CC-486 (see the Azacitidine IB).
History of allergic reaction/hypersensitivity attributed to compounds containing boron, mannitol, polysorbate 80 or sodium citrate dehydrate
Patient has hypersensitivity to bortezomib, boron, or mannitol
Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Known hypersensitivity to bortezomib, boron, or mannitol
History of allergy to mannitol
Known allergy to bortezomib, boron, or mannitol
Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known or suspected hypersensitivity to 5-azacitidine, romidepsin, mannitol or other agents used in this study
Hypersensitivity to boron or mannitol, or compounds containing these components
Patient has hypersensitivity to bortezomib, boron or mannitol
History of allergic reactions to compounds containing boron, mannitol, VELCADE
Known hypersensitivity to any components of pracinostat, azacitidine, or mannitol
History of sensitivity to mannitol
Hypersensitivity to bortezomib, boron, or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
No history of hypersensitivity to bortezomib, boron or mannitol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to mannitol
Known hypersensitivity to bendamustine or mannitol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Hypersensitivity to VELCADE, boron, mannitol, or any other component of protocol therapy
Known hypersensitivity to bortezomib, boron, or mannitol
Known or suspected hypersensitivity to 5'-azacitidine or mannitol
Allergy to mannitol
Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.
Patient has hypersensitivity to bortezomib, boron or mannitol
Patient has a history of allergic reaction attributable to bortezomib or other compounds containing boron or mannitol (Phase 1b and 2a only)
Known or suspected hypersensitivity to ofatumumab, bendamustine or mannitol.
Known hypersensitivity to bendamustine, mannitol, or other study-related drugs
Hypersensitivity to azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
History of sensitivity to mannitol
Known or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibody
Patients with hypersensitivity to bortezomib, boron or mannitol
Patients with hypersensitivity to bortezomib, boron or mannitol
Known or suspected hypersensitivity to azacitidine, pembrolizumab or the excipients of any of the study drugs (including mannitol). Known or suspected hypersensitivity to monoclonal antibodies.
Previous treatment with talazoparib
Known hypersensitivity to any of the components of talazoparib
Prior treatment with talazoparib
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any of the components of talazoparib
Patients who have had prior BMN673 (talazoparib) therapy
Known hypersensitivity to any of the components of talazoparib
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Female patients may not be breastfeeding at the first dose of talazoparib and must not breastfeed during study participation through 45 days after the last dose of talazoparib.
Patients with a history of allergic reaction to irinotecan, cephalosporins or a severe penicillin allergy are not eligible
Prior allergic reaction to the hormones involved in this protocol
Prior allergic reaction to the study drug(s) involved in this protocol
Prior allergic reaction to carboplatin, paclitaxel, and/or cisplatin
Patients who are allergic to milk
Must not have known allergic reaction against any of the components of the study treatment
Previous allergic reaction to an immunomodulatory drug (IMiD)
Use of steroids for non-tumor indications (for example: asthma or severe allergic reaction) is permitted
History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.
Patients may not have a history of allergic reaction or hypersensitivity to microcrystalline cellulose (Avicel PH302) or polysorbate 80 (Tween 80), which are components of the drug product MGCD516
History of allergic reaction to docetaxel
Any history of allergic reaction to chemotherapies used
History of allergic reaction to alpha-1-antitrypsin.
Patients with hypersensitivity or other allergic reaction to platinum chemotherapy.
Patients with hypersensitivity or other allergic reaction to taxanes.
Known allergic reaction to antibiotics of the aminoglycoside group (ie, streptomycin, gentamicin)
History of allergic reaction (including erythema nodosum) to lenalidomide
Allergic reaction to single-agent rucaparib or irinotecan
Prior allergic reaction or known intolerance to irinotecan
If in Arm G, significant allergic reaction to cisplatin.
Prior allergic reaction to cisplatin
Patients with a history of severe allergic reaction to cisplatin or carboplatin
Patient with prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
History of anaphylaxis or serious allergic reaction to carboplatin or paclitaxel
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
Prior allergic reaction to cisplatin
History of allergic reaction to interleukin-2 or nivolumab
Prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug (e.g., hypersensitivity or allergy to murine products).
History of any serious adverse reaction or hypersensitivity to cytarabine, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor
The subject has a history of serious allergic reaction to any substance, resulting in hospitalization or requiring other emergent medical attention
History of allergic reaction to DSF or Cu
Allergic to temozolomide (TMZ)
History of allergic reaction to intravenous iodinated contrast media is not contraindication to the study; patients with history of mild allergic reaction to iodinated contrast media will be premedicated with 40 mg of prednisone orally (p.o.) 12 and 2 hours (hrs) before the transarterial chemoperfusion treatment to prevent allergic reaction; patients with history of moderate and severe allergic reaction to iodinated contrast media or patients with history of mild allergic reaction to iodinated contrast media despite adequate premedication will undergo angiogram using carbon dioxide or a gadolinium based contrast agent
History of allergic reaction to natalizumab
Known serious allergic reaction to vandetanib or metformin
Prior allergic reaction to the study drug(s) involved in this protocol
Any allergic reaction to a previously administered monoclonal antibody or other therapeutic protein
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
Prior allergic reaction to temozolomide
Previous severe or life-threatening allergic reaction with rituximab or known allergy to the compounds found in INCB7839
Prior allergic reaction to the hormones involved in this protocol
Patients with known history of allergic reaction to intravenous (IV) contrast material that is not amenable to pre-treatment by University of Alabama at Birmingham (UAB) protocol
History of Grade 3 or higher allergic reaction with prior asparaginase treatment,
No prior known allergic reaction to monoclonal antibodies
History of >= 2 allergic reaction or any grade anaphylactic reaction during prior administration of tocilizumab
Subject has prior severe allergic reaction or intolerance to a monoclonal antibody, including humanized or chimeric antibodies.
Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.
Previous allergic reaction to radioisotope bone tracers
Known history of serious allergic reaction including anaphylaxis or Stevens- Johnson syndrome/ toxic epidermal necrolysis
History of any hypersensitivity or allergic reaction to any beta lactam antibiotic, tazobactam, or any study therapy (IV or oral)
Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or any of study drug excipients
Patients with a lifetime history of dermatitis as an allergic/toxic reaction to any medication
Prior allergic reaction to cetuximab
History of severe allergic reaction, including erythema nodosum, to lenalidomide
Patients who are allergic to micafungin and/or voriconazole or any of their ingredients
Documented severe allergic reaction to intravenous (IV) iodinated contrast, specifically bronchospasm and anaphylaxis
Prior known allergic reaction to pembrolizumab or its excipients
Prior allergic reaction to cisplatin
Patients with any history of allergic reaction to paclitaxel or other taxanes or carboplatin
Prior allergic reaction to the study drug(s) involved in this protocol
Patients will be excluded if there is any history of allergic reaction(s) attributed to compounds of similar composition to temsirolimus, sorafenib, their metabolites, or any component of their formulation (including excipients and polysorbate 80); this includes hypersensitivity to macrolide antibiotics due to potential for cross-reactivity with temsirolimus
History of clinically significant allergic reaction attributed to any injected\n             compound.
Prior allergic reaction to any of the study drugs involved in this protocol
Prior allergic reaction to the study drug(s) involved in this protocol
Prior allergic reaction to the study drugs involved in this protocol or to a monoclonal antibody
Known contraindication to dexamethasone (allergic reaction or systemic fungal infection)
Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
Known history of allergic reaction to cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
Known allergic reaction to any component of MEDI1873
Prior allergic reaction to cetuximab
History of significant adverse or allergic reaction to any component of G100 and, if enrolled in Part 2, anti-PD1 antibodies.
Patients must not have a known allergic reaction to epoetin alfa (Procrit) or human serum albumin
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
Prior allergic reaction to the study drugs.
Prior allergic reaction to the study drugs involved in this protocol
Known allergy or past administration reaction including infusion related reaction (IRRs), anaphylactic, or anaphylactoid reactions to any component of the CDX-0158 formulation.
Known major adverse reaction/event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)
Has prior allergic reaction to bevacizumab
History of allergic reaction to parenteral administered recombinant protein product
Prior allergic reaction to the study drugs (cisplatin, mitomycin, fluorouracil [5FU]) involved in this protocol
Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin;
Prior allergic reaction to the drugs involved in this protocol
Patients with history of allergic reaction to metformin
Patients with history of allergic reaction to minocycline or to any of the tetracyclines
Prior allergic reaction to temozolomide
Prior allergic reaction to 5-FU or oxaliplatin
History of >= grade 3 allergic reaction to mFOLFOX6 (patients successfully desensitized to oxaliplatin are eligible or those willing to undergo desensitization during the first two cycles of mFOLFOX6 per institutional guidelines)
History of an allergic reaction or intolerance to irinotecan
History of allergic reaction (including erythema nodosum) to lenalidomide
Prior allergic reaction or severe intolerance to either irinotecan or temozolomide
History of allergic reaction to docetaxel
History of allergic reaction to disulfiram
Any known contraindications to sorafenib including allergic reaction, pill-swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant gastrointestinal (GI) bleed within 30 days, metastatic brain disease, renal failure requiring dialysis
Prior allergic reaction to temozolomide.
Prior allergic reaction to the study drug (bevacizumab)
Hypersensitivity to the active substance or to any of the excipients for study drug BT062, or history of severe allergic or anaphylactic reaction to therapeutic proteins (e.g. reaction to vaccination or to biological therapy)
Known history of allergic reaction to cremophor/paclitaxel
Significant allergic reaction to iodinated contrast
Prior allergic reaction to trastuzumab for the treatment of metastatic breast cancer
Prior allergic reaction to the study drugs involved in this protocol
History of allergic reaction to ATRA
History of allergic reaction to dasatinib
Patients who have previously been administered basiliximab or who have had an allergic reaction to basiliximab or one of its components in the past will be excluded
History of serious allergic reaction, including anaphylaxis and toxic epidermal necrolysis
Known contraindication to standard-of-care sorafenib including allergic reaction, pill swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant GI bleed within 30 days, renal failure including dialysis
History of allergic reaction to a structural compound or biological agent similar to TH-302
Prior allergic reaction to the study drug(s) involved in this protocol
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
History of serious allergic reaction to yeast or yeast-derived products, including known or suspected hypersensitivity reaction to sargramostim;
Experienced a Grade 3 or higher hypersensitivity reaction to monoclonal antibodies or other therapeutic proteins, and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as antihistamines, 5-hydroxytryptamine (5-HT3) receptor antagonists, or corticosteroids;
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
History of an allergic reaction to Human Serum Albumin
History of severe allergic or hypersensitivity reaction to other therapeutic antibodies that required discontinuation of therapy
Prior confirmed allergic reaction (including moderate rash, dyspnea, wheezing, urticaria or other symptoms) attributed to the administration of either anthracyclines or other liposomally encapsulated drugs that required discontinuation of prior therapy.
Patients with known allergic reaction to lamivudine or tenofovir DF
Known allergic reaction to nickel
History of allergic reaction to ivabradine
Patients with a history of allergic reaction to ropivacaine or other local amide anesthetics
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation
Porphyria (possibility of triggering a porphyric reaction)
No history of (H/O) allergic reaction to iron therapy
Allergic to yogurt
History of drug sensitivity or allergic reaction to alpha- or beta-blockers
Prior allergic reaction to memantine (memantine hydrochloride)
History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation or to latex
Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis or any other serious adverse reaction to any of the anesthetics or analgesics medications used in the study
Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to the medication used in the study
Patient with known allergic or hypersensitivity reaction to rHUPH20 or any hyaluronidase extracts
Allergic reaction to carbamazepine or oxcarbazepine (major histocompatibility complex, class I, B [HLA-B]*1502)
History of allergic or other adverse reaction to venlafaxine or SSRI’s
Patients with a history of a severe allergic reaction (anaphylaxis)
History of drug sensitivity or allergic reaction to alpha or beta-blockers
History of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents
History of severe allergic reaction to obinutuzumab
A history of adverse reaction to IV thiamine
Not be allergic to any cruciferous vegetables (e.g.: broccoli, cauliflower, kale, brussels sprouts, arugula/rocket, bok choy, etc.)
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
Allergic reaction to omeprazole
Allergic reaction to vitamin D
Allergic reaction to metformin
Any known allergic reaction to vaccine components
Patients with a known history of allergic reaction to ethanol, nitroglycerin, or citrate
life threatening allergic reaction to food and/or drugs
History of reaction to ICG, iodides, or technetium radiocolloid
Patient not able to tolerate MRI scan due to claustrophobia or severe pain or allergic reaction to contrast
Patients with renal failure or history of allergic reaction to Gadavist will be excluded
Known history of allergic reaction to magnetic resonance (MR) contrast material
Participants with multiple drug allergies, and/or subjects who have had an allergic reaction to any intravenous iron replacement product, or a known history of hypersensitivity to ferumoxytol
Previous allergic reaction to contrast medium
Allergic to common dentifrice ingredients
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
Patients with a history of allergic reaction to latex or gadolinium containing intravenous contrast agents
History of severe allergic/hypersensitivity reaction or significant transfusion reaction.
Patients who have had an adverse reaction to oxytocin
Women with hypersensitivity to phenylmethane compounds, or a history of allergic reaction to iodides
History of allergic reaction to MR contrast media
History of allergic reaction to compounds of similar composition to ferumoxytol (e.g. IV iron)
History of severe allergic-like reaction to iodinated contrast media
Known hypersensitivity to any component of bevacizumab
Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI4736) and/or tremelimumab formulation
Known hypersensitivity to any component of the formulation or substituted benzimidazoles
Patients with known hypersensitivity to any component of the chemotherapy regimen will not be eligible
Known hypersensitivity to any component of bevacizumab
Known prior severe hypersensitivity to the investigational products or any component in their formulations,
Known hypersensitivity to any component of the atezolizumab or cobimetinib formulations
Known hypersensitivity or allergy to murine products or any component of the obinutuzumab, rituximab, idasanutlin, or venetoclax formulation
History of hypersensitivity reactions to study drug or any component of the study drug formulation
Known hypersensitivity to any study drug component
Known hypersensitivity to any component of required drugs in the study
Participation in the DES component of the study.
Known allergy or reaction to any component of either study drug formulation
Known allergy or hypersensitivity to any component of the atezolizumab formulation
The tumor must not have an infratentorial component;
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
Known allergy or reaction to any component of either study drug formulation
Known hypersensitivity to any component of study drug including potential subjects with a history of major immunologic reaction to any IgG-containing agent
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known allergy or reaction to any component of either study drug formulation
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
An allergy to a component of Levulan
have a known or suspected allergy to the study drug or any study drug component;
Known hypersensitivity or allergy to any component of the avelumab formulation
Known hypersensitivity to any component of the investigational products
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known hypersensitivity to an component of bevacizumab
Known allergy or hypersensitivity to any component of the investigational drug product.
Known hypersensitivity to any component of the nivolumab or ipilimumab product
Known hypersensitivity to immunoglobulins or any other component of the study drug
Known hypersensitivity to any component of the investigational product
Known hypersensitivity to 5-fluorouracil, capecitabine, bevacizumab or to any component of the investigational products or compounds of similar chemical composition
Known hypersensitivity to any study drug component.
Known hypersensitivity to any component of the product (lenvatinib or ingredients).
Serum M component (? 0.5 g/dL), or
History of hypersensitivity to any component of the formulation
History of hypersensitivity to active or inactive excipients of any component of treatment
Known allergy or reaction to any component of the MEDI4736 formulation or its excipients
Known hypersensitivity to any component of bevacizumab
Known contraindication or hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of Avastin
Patient with documented hypersensitivity to any of the component medications
History of hypersensitivity to any component of the formulation
History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation
History of hypersensitivity to any component of the formulation
Known hypersensitivity to any component of topotecan or doxorubicin or other required drugs in the study
Known hypersensitivity to any component of the study medication(s).
Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.
Known prior severe hypersensitivity to investigational products or any component in their formulations
Participant has hypersensitivity to any component of TMZ or dacarbazine.
Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).
Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material
DOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
DOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
Known prior or suspected hypersensitivity to study drugs or any component in their formulations
Hypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL-2 or any component of the formulation
History of allergy or hypersensitivity to any component of the treatment
Hypersensitive or intolerant to any component of the study drug(s) formulation
Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
Patients with a history of hypersensitivity to sirolimus or any component of the formulation.
Known hypersensitivity to any study drug component
Patients must not have any known allergy or reaction to any component of the MEDI4736 formulation
Known allergy or hypersensitivity to any component of the atezolizumab formulation
Known allergy or hypersensitivity to any component of the bevacizumab formulation
Known hypersensitivity to any component of lenvatinib or midazolam.
Known hypersensitivity to a component of protocol therapy
Known hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study products
Known hypersensitivity to any study drug component including thapsigargin derivatives, polysorbate 20, or propylene glycol
History of hypersensitivity to any component of the formulation.
Patients with a known hypersensitivity to any component of bevacizumab are not eligible for this trial
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation
Extensive intraductal component
Known immediate or delayed hypersensitivity reaction to carboplatin, paclitaxel, polysorbate 80, or any other component of the formulation
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to 5-fluorouracil or to any component of the investigational products or compounds of similar chemical composition
Has a known hypersensitivity, intolerability or contraindication to any component of study treatment, including premedication
Participants who have known hypersensitivity to any component of loperamide or budesonide
Patients with a known hypersensitivity to any component of bevacizumab are not eligible for participation
History of allergy or hypersensitivity to any component of the study drugs
Known or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexed
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of bevacizumab
Subjects with less than 25% intraductal component
Known hypersensitivity to any component of the trial agents
Known hypersensitivity to any component of the formulation
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide long-acting release [LAR] formulations
History of hypersensitivity to any component of the formulation
Known hypersensitivity to any component of bevacizumab
CARBOPLATIN ARM: hypersensitivity to carboplatin or any component of the formulation
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of bevacizumab and osimertinib
Patients with known hypersensitivity to any component of bevacizumab
History of allergy or reaction to any component of the MEDI-551 formulation
History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI; hypersensitivity skin test is required at screening to rule out allergy to S. cerevisiae
Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.
Known hypersensitivity to any component of recombinant protein production by CHO cells
Known allergy or hypersensitivity to any component of the study treatment(s)
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
Hypersensitivity to PEG or other component of AEB1102 (Co-ArgI-PEG)
Known hypersensitivity to any component of atezolizumab formulation or other study medication
Known hypersensitivity to any component of study treatments
Known hypersensitivity to any component of study treatments
Known hypersensitivity to bevacizumab or any component of its formulation
Subject has a known history of serious hypersensitivity to ASP2215, or any component of the formulation used.
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
Known hypersensitivity to any component of study treatments
Previous known sensitivity to any Fibrin Sealant Grifols component or any Surgicel® component.
Known allergy or hypersensitivity to any component of the formulation of CA-4948 used in this study
Known or suspected hypersensitivity to any component of GVAX Pancreas vaccine or CRS-207, or known allergy to both penicillin and sulfa
Subjects who are known or suspected to be hypersensitive to any component of the study medications.
Allergic to diphtheria toxin a component of the study drug A-dmDT390-bisFv(UCHT1).
Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.
Known hypersensitivity to any component of RDHAP
Known hypersensitivity to somatostatin analogs or any component of the pasireotide long acting release (LAR) or suspension concentrate (s.c.) formulations
Known hypersensitivity to any component of the atezolizumab product
Known hypersensitivity reaction to any component of ferric carboxymaltose
Patients with known hypersensitivity to NT-I7 or any component used in the vehicle/formulation are ineligible
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of testosterone
Hypersensitivity/allergy or contraindication to any component of the stent, delivery system, or medication required to complete the procedure,which in the investigator's opinion cannot be adequately premedicated
Educational component: men over the age of 18
Screening component: men over age 40
Documented hypersensitivity to any component of ranolazine (Ranexa) pills
History of hypersensitivity or allergic reaction to NRT, or any component of its formulation
Any known allergy or hypersensitivity to vaginal lubricants or any component of study product
Known hypersensitivity to any component of the nivolumab or ipilimumab product
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
History of allergy or hypersensitivity to any component of the treatment
Patients with known hypersensitivity or allergy to any component of Sonazoid.
Patients with known hypersensitivity or allergy to any component of Definity
Hypersensitivity to NVB or any of its excipients or to any component of AVD + BV therapy
Patients with known hypersensitivity to any component of Definity micro bubble contrast
Known hypersensitivity to gemcitabine or any component of the formulation.
History of allergy to study drug components
History of allergy to study treatments or any of its components of the study arm that participant is enrolling
Patients with a history of allergy to the study drug components are excluded
Any history of allergy to the study drug components
History of allergy to study drug components
History of allergy to study drug components
History of allergy or intolerance to study drug components or polysorbate-80-containing infusions
History of allergy or hypersensitivity to study drug components
History of allergy to study drug components.
Any history of allergy to the study drug components
Known allergy to the study drugs or any of its components
Any history of allergy to the study drug components
History of allergy or intolerance (unacceptable adverse event) to study drugs components.
History of allergy to study drug components
History of allergy to study drug components
History of allergy to study drug components
History of allergy or adverse drug reaction to study components
History of allergy to study drug components
History of allergy to components of nivolumab or DS-8273A, or known allergy to other antibody therapies
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
History of allergy to study drug components
No contraindication to receiving radiotherapy and no known allergy to components of fresolimumab
History of allergy to study treatments or any of its components of the study arm that participant is enrolling
History of allergy to study drug components
History of allergy or hypersensitivity to nivolumab components
History of allergy to study drug components
Known allergy to any of the treatment components
Known allergy/hypersensitivity to drug or components
History of allergy or hypersensitivity to nivolumab drug components.
History of allergy or hypersensitivity to any of the study drugs or study drug components
Any history of allergy to the study drug components
History of allergy to study drug components.
Local or severe allergy to any components of the drug regimen.
Patient must not have a known allergy to any of the treatment components
Subject has a history of allergy or hypersensitivity to study drug components;
Have known allergy or hypersensitivity to any components of study treatment.
History of allergy to components of ipilimumab or panobinostat, or known allergy to other antibody therapies
Subject has a known allergy to ART-123 or any components of the drug product.
Allergies and Adverse Drug Reaction: History of allergy to study drug components
History of allergy to study drug components
History of allergy or intolerance (unacceptable adverse event) to study drugs components
Known allergy to any of the vaccine or adjuvant components, including eggs
Known allergy or adverse drug reaction to nivolumab, or a history of allergy to study drug components
Known allergy to any of the treatment components
The patient has known allergy to any of the treatment components
History of allergy to study drug components
History of allergy to nivolumab components
Known allergy to paclitaxel or any of its components
The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components.
Allergy / history of hypersensitivity reaction to any of the treatment components
History of allergy to study drug components
History of known allergy to components of the study supplements
Known allergy to any of the treatment components.
Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
Allergy to yeast or any of the components of Gardasil
History of allergy to any of the components of OTL38, including folic acid
History of allergy to any of the components of OTL38, including folic acid
Allergy to lidocaine, fentanyl, midazolam, or propofol (may be used during tumor biopsy or injection)
Patient has a history of hypersensitivity to fentanyl or opioids
Patients who are allergic to or not tolerant of EMLA cream, propofol, or fentanyl will be excluded
History of allergy to fentanyl
Allergy to fentanyl
History of allergy to fentanyl
History of allergy to fentanyl
All patients with transdermal patches (e.g.; fentanyl, Lidoderm, scopolamine, etc)
Known allergy, hypersensitivity or contraindication to components of the FPA144 formulation including polysorbate or to platinum-containing medications, 5-FU, or leucovorin
Allergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.
Known hypersensitivity to Apatinib or components of the formulation.
Known allergy or hypersensitivity to the components of the atezolizumab formulation.
The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
A previously identified allergy or hypersensitivity to components of the study treatment formulation.
Allergy or hypersensitivity to components of the cobimetinib formulation
Has known allergy or reaction to any component of either study drug or formulation components
Allergy or hypersensitivity to components of the vemurafenib formulation
ENTRECTINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of entrectinib formulation
A previously identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Previously identified allergy or hypersensitivity or intolerance to components of the study treatment formulation (cyclophosphamide, capecitabine, lapatinib [lapatinib ditosylate], trastuzumab)
Known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL)
The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
Subject with known or suspected hypersensitivity to seviteronel, or any components of the formulation
Known allergy or hypersensitivity to components of the FPA144 formulation including polysorbate
For the Combination Dose Finding and Combination Expansion cohorts only: previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumab
Known hypersensitivity to any of plitidepsin's formulation components
Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.
The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
The participant has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Subject has a known or suspected hypersensitivity to enzalutamide or any components of the formulation used.
Known allergy or hypersensitivity to any of the formulation components
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
Allergy or hypersensitivity to components of either study drug formulation
Allergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulation
Known hypersensitivity to any involved study drug or any of its formulation components
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Allergy or hypersensitivity to components of the vemurafenib formulation
Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation
Allergy or hypersensitivity to components of the GDC-0994 formulation
Allergy or hypersensitivity to components of the cobimetinib formulations
No known history of severe hypersensitivity reactions to any of the components of efatutazone or paclitaxel formulations
Previously identified allergy or hypersensitivity to components of the cabozantinib formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Previously identified hypersensitivity to components of the formulations used in this study
Known allergy or hypersensitivity to the components of the doxorubicin, cyclophosphamide, carboplatin, or paclitaxel formulations.
Known allergy or hypersensitivity to liposomal or pegylated G-CSF formulations.
Known allergy or hypersensitivity to the components of the formulations of atezolizumab, nab-paclitaxel, cyclophosphamide, or doxorubicin, filgrastim or pegfilgrastim
Known allergy or hypersensitivity to phosphatidylinositol 3 kinase (PI3K) inhibitors or any component of the formulations used in this study.
History of severe hypersensitivity reactions to components of the cobimetinib, atezolizumab, or pembrolizumab formulations
Previously identified allergy or hypersensitivity to any component of the study treatment formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Has a previously identified allergy or hypersensitivity to components of the study treatment formulations
Known allergy or hypersensitivity to study drug formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Patients with a known allergy to any component of the study treatment formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Patients must not have any known allergy or reaction to any component of the nivolumab and ipilimumab formulations
Known allergy or hypersensitivity to IP formulations or to other human monoclonal antibodies
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Allergy or hypersensitivity to components of the cobimetinib formulations
Patient has a known allergy to any component of the study treatment formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations.
Allergy or hypersensitivity to components of the cobimetinib formulations
The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulations.
History of serious allergy or reaction to any component of RICE or RDHAP formulations that would prevent administration
